Animerra
Boston, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into Animerra
Animerra develops next-generation biologics for companion animal health, applying therapeutic innovation from human medicine to veterinary treatment. The company targets pet owners and veterinary markets with innovative protein-based therapeutics and biologics treatments.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.5M disclosed across 1 round · 2025
▶$6.5MraisedFeb 2025 · 1 investors · Other Health CareRule 506(b)
▶$6.5MraisedFeb 2025 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Anna RathExecutive Officer
- Offering amount
- $20M
- Amount sold
- $6.5M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
ANI Pharmaceuticals5 shared keywordsANI Pharmaceuticals is a generic and specialty pharmaceutical company that develops, manufactures, and distributes prescription drugs across multiple therapeutic areas including generics, rare diseases, and established branded products.
VISTERRA, INC.4 shared keywordsA biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
Invenra4 shared keywordsInvenra develops proprietary platform technologies to discover and develop novel bi- and multi-specific antibody therapies, with an initial focus on oncology. The company is advancing pipelines of antibody candidates with partners and intends to expand into additional disease categories.
BIOVECTRA3 shared keywordsBIOVECTRA is a contract development and manufacturing organization (CDMO) with research and development capabilities in biologics process development, complex chemistry, and analytical development. Its work spans recombinant proteins, viral vectors, mRNA vaccines, and pharmaceutical process development for the biotech and pharmaceutical industries.
Neumora Therapeutics3 shared keywordsNeumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
Azitra3 shared keywordsAzitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology. The company leverages a proprietary platform combining a microbial library of approximately 1,500 bacterial strains with AI/ML-powered screening and genetic engineering technology.
Companies competing with Animerra for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Animerra do?
- Animerra develops next-generation biologics for companion animal health, applying therapeutic innovation from human medicine to veterinary treatment. The company targets pet owners and veterinary markets with innovative protein-based therapeutics and biologics treatments.
- Who are Animerra's investors?
- Animerra's investors include Anterra Capital.
- How much funding has Animerra raised?
- Animerra has disclosed $6.5M raised across 1 round.
- Where is Animerra headquartered?
- Animerra is headquartered in Boston, US.